Laser and 'Skin Booster' injection may reverse sun damage and prevent cancer
NCT ID NCT07680426
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests whether combining a fractional laser with a biostimulator (poly-L-lactic acid) can repair sun-damaged skin better than either treatment alone. The goal is to improve skin health and potentially lower the risk of skin cancer. Researchers will use AI-assisted imaging and genetic analysis to measure changes in the skin. The trial involves 33 adults with signs of chronic sun damage.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Poly-L-lactic acid (Sculptra)
- What this could lead to
- If it works, this approach could offer a non-surgical way to reverse sun damage and reduce the risk of skin cancer.
- What could go wrong
- This is a small, early-stage study with 33 participants, so results may not apply to everyone. Laser and injections carry risks like redness, swelling, or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 33 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years * Clinical signs of photodamage. Signs will include low-grade actinic keratoses (Olsen grade I-II), solar lentigines, telangiectasia, or other visible markers of chronic photodamage. Exclusion Criteria: * Active skin diseases in the treatment site * Laser treatment, PLLA, or other treatments in the treatment area within the past 24 months * Pregnancy or breastfeeding * Contraindications to AFL or Sculptra
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Photodamaged skin are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Bispebjerg Hospital
Copenhagen, Capital Region, 2400, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cream and light combo reverse crepey skin?
- Can text messages and facebook groups prevent skin cancer in teens?
- Filler combo aims to restore cheek volume after weight loss
- Numbing cream showdown: which one wins for laser pain?
- Smartphone screening could catch skin cancer sooner
- Can a website help you spot skin cancer? singapore trial aims to find out